Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children.
We studied if the beneficial effects of bisphosphonates are maintained after their discontinuation, and whether adverse effects may develop. Seventeen children in whom I.V. bisphosphonates were discontinued for at least 12 months were included. Fracture rate (FR), skeletal pain, bone mineral density of total body (TB) and spine L(2-4), skeletal radiographs, bone markers and kidney functions were compared between: (a) before treatment, (b) end of treatment, and (c) last follow-up. Mean treatment duration was 22+/-2 months (6-43) and follow-up 26+/-2 months (18-44). FR (mean +/- SD) decreased from 0.74+/-0.21/year before treatment to 0.35+/-0.11/year after treatment and 0.20+/-0.09/year at follow-up (p
Pediatric nephrology (Berlin, Germany)
Adolescent; Bone Density; Bone Diseases, Metabolic; Child; Child, Preschool; Diphosphonates; Female; Follow-Up Studies; Humans; Male; Osteogenesis; Osteoporosis; Retrospective Studies; Time
Waterhouse, K. M., Auron, A., Srivastava, T., Haney, C. J., Alon, U. S. Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children. Pediatric nephrology (Berlin, Germany) 22, 282-287 (2007).